Jim Cramer likes Pfizer and recommends buying more stock. Six Flags is struggling, but Cramer likes First Solar and Equity ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher ...

The vaccine will be Moderna’s second product to enter the U.S. market after the FDA’s approval of the biotech company’s COVID ...

Moderna's Spikevax KP.2 targets the KP.2 variant of the virus. The U.S. Food and Drug Administration has also approved the shot, as well as updated vaccines from Pfizer and BioNTech. Moderna (MRNA ...

Opens in a new tab or window The FDA approved and granted emergency use authorization for updated 2024-2025 mRNA COVID-19 vaccines from Moderna (Spikevax) and Pfizer-BioNTech (Comirnaty), the ...

A potential FDA proposal would label Goldfish “medium” in saturated fat and sodium. (The placement and size of any U.S. label has yet to be determined.) The same product would bear stop-sign ...

It can perform a host of tasks beyond just putting words down, including a very handy function for creating mailing labels. In this guide, we're going to show you how to print labels from Word ...

Moderna developed the Spikevax COVID-19 vaccine, and regulators approved this year its vaccine for RSV or respiratory syncytial virus. The company also has a combination flu/COVID vaccine and an ...

Image Source: Zacks Investment Research Spikevax, targeting the variant JN.1., is currently approved in the United States, the United Kingdom, Japan and Taiwan. Last month, the FDA approved ...

Until now, Canada has only had access to vaccine formulas that were approved in fall 2023 and target the Omicron XBB.1.5. Moderna's latest formulation of their mRNA vaccine, Spikevax, targets the KP.2 ...